Trial reportNature medicine2025
Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.
Trial report in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03249090 ("PRO-TECT" Patient Reported Outcomes to Enhance Cancer Treatment), which is not on this map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
"PRO-TECT" Patient Reported Outcomes to Enhance Cancer Treatment
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effectiveness of digital health interventions for the management of Low Anterior Resection Syndrome (LARS) after sphincter-preserving surgery for rectal cancer: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Factors associated with response to patient-reported outcome measures: a systematic review of systematic and scoping reviews, and meta-analyses.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Pooled it
- Factors associated with unplanned healthcare encounters in pediatric cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Trial
- Benefit of adding Cureety Techcare telemonitoring to usual care during injectable anticancer treatment: the OPTIMACURE multicentric French prospective randomized study.BMC health services research · 2025Trial
- Patient and staff experiences with an EHR-Integrated Symptom Management Program (eSyM) in oncology.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Electronic Patient-Reported Outcomes With Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy: The PRO-DUCE Randomized Clinical Trial.JAMA network open · 2025Trial
- Chest wall pain as a late effect following radiotherapy for breast cancer: A systematic review of prevalence and risk factors.Technical innovations & patient support in radiation oncology · 2026Review
- Digital symptom monitoring in cancer care: an exploratory evaluation of low uptake and engagement.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- From Patient Voice to Organizational Adaptability: A Critical Narrative Review and Conceptual Model for Personalized Care.Healthcare (Basel, Switzerland) · 2026Review
- Practical Insights from Operationalizing a Remote Symptom Monitoring Program Using a Commercial Platform in a Canadian Community Cancer Clinic: A Post-Implementation Qualitative Evaluation.Current oncology (Toronto, Ont.) · 2026Article
- Natural language processing-based model to predict radiation pneumonitis in patients with locally advanced non-small cell lung cancer undergoing chemoradiotherapy: a retrospective cohort study.EClinicalMedicine · 2026Article
- Patient-reported outcomes in Australian oncology: from emerging practice to system-wide care.Internal medicine journal · 2026Article
- Fatigue: assess and address it.Journal of patient-reported outcomes · 2026Article
- Artificial intelligence in oncology: linking biological discovery to clinical utility.Molecular cancer · 2026Review
- Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Randomized Clinical Trial.JAMA oncology · 2026Article
- An Agentic Multimodal Sensing Architecture for CT-Guided Wearable and Respiratory Monitoring in Oncology Care.Sensors (Basel, Switzerland) · 2026Article
- Article
- From static prediction to dynamic cancer trajectories: Virtual Human Twins for breast cancer decision support.PLOS digital health · 2026Article
- Concordance Between Patient-Reported and Clinically Documented Symptoms in Acute Myeloid Leukemia.Oncology nursing forum · 2026Article
- Supportive care for talquetamab-related dysgeusia in multiple myeloma: mixed-methods evidence, nutrition-focused flowchart, and digital companion concept.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
Symptoms are often underdetected during cancer treatment. To determine if symptom monitoring with electronic patient-reported outcomes (PROs) improves clinical outcomes, we conducted a cluster-randomized trial in which 52 oncology practices were assigned to PRO or usual care. At PRO practices, patients with metastatic cancer were invited to complete weekly symptom surveys. Severe or worsening symptoms generated alerts to the care team. The primary outcome was overall survival, and secondary outcomes included emergency visits, time to deterioration of physical function, symptoms, health-related quality of life (HRQL) and patient satisfaction with PRO. Among 1,191 enrolled patients, there was no difference in survival (hazard ratio (HR) 0.99 (95% confidence interval (CI), 0.83-1.17); P = 0.86). Time to first emergency visit was significantly prolonged with PRO compared to usual care (HR 0.84 ((95% CI, 0.71-0.98); P = 0.03), with a 6.1% reduction in the cumulative incidence of emergency visits and fewer mean visits at 12 months with PRO (1.02 versus 1.30; P < 0.001). Benefits also significantly favored PRO for delayed deterioration of physical function (median 12.6 versus 8.5 months, HR 0.73; P = 0.002), symptoms (12.7 versus 9.9, HR 0.69; P < 0.001) and HRQL (15.6 versus 12.2, HR 0.72; P = 0.001), which remained significant when considering deaths in analyses. Most patients felt that PRO improved discussions with the care team (77.0% (188/244)), made them feel more in control of their care (84.0% (205/244)) and would recommend it to other patients (91.4% (223/244)). Patients completed 91.5% (20,565/22,486) of expected weekly symptom surveys. These findings demonstrate that symptom monitoring with PRO meaningfully improves clinical outcomes, the patient experience and utilization of services and should be included as a standard part of quality cancer clinical care. Future studies of PRO in clinical care should focus on these outcomes rather than mortality as primary endpoints. ClinicalTrials.gov registration: NCT03249090.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.